HBV recurrence in chronic hepatitis B treated with lamivudine after prolonged seroconversion and long-term treatment with lamivudine.

被引：0
|
作者：
Gutfreund, KS
Addison, WR
Williams, M
Fischer, KP
Tyrrell, DLJ
机构：
[1] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada
[2] Univ Alberta, Dept Med Microbiol, Div Gastroenterol, Edmonton, AB, Canada
来源：
HEPATOLOGY | 1998年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1298
引用
收藏
页码：487A / 487A
页数：1
相关论文
共 50 条
  • [41] Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation
    Rayes, N
    Seehofer, D
    Hopf, U
    Neuhaus, R
    Naumann, U
    Bechstein, WO
    Neuhaus, P
    TRANSPLANTATION, 2001, 71 (01) : 96 - 101
  • [42] Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients
    Idilman, R.
    Cinar, K.
    Seven, G.
    Bozkus, Y.
    Elhan, A.
    Bozdayi, M.
    Yurdaydin, C.
    Bahar, K.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (03) : 220 - 226
  • [43] Long-term effect of lamivudine treatment in patients with chronic hepatitis B: Efficacy and durability of response after cessation of treatment.
    Hong, SP
    Han, KH
    Ahn, SH
    Paik, YH
    Youn, YH
    Chon, CY
    Moon, YM
    HEPATOLOGY, 2000, 32 (04) : 587A - 587A
  • [44] Short-term lamivudine for the treatment of chronic hepatitis B
    Yotsuyanagi, H
    Yasuda, K
    Iino, S
    INTERVIROLOGY, 2003, 46 (06) : 367 - 372
  • [45] Prophylaxis of hepatitis B reinfection after liver transplantation with HBIg and lamivudine.
    Rosenau, J
    Bahr, MJ
    Tillmann, HL
    Klempnauer, J
    Manns, MP
    Boeker, KH
    GASTROENTEROLOGY, 2000, 118 (04) : A1483 - A1483
  • [46] Lack of toxicity in patients with chronic HBV infection treated with a 6 months course of lamivudine.
    Honkoop, P
    deMan, RA
    Francke, J
    vandeBerg, JWO
    Zondervan, PE
    Schalm, SW
    HEPATOLOGY, 1996, 23 (01) : P130 - P130
  • [47] The long-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States.
    Dickens, T
    Raasch, RH
    Saal, GB
    Yeh, YC
    HEPATOLOGY, 2000, 32 (04) : 590A - 590A
  • [48] Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B
    Luiz Caetano Da Silva
    João Renato Rebello Pinho
    Roberta Sitnik
    Luís Edmundo Pinto Da Fonseca
    Flair José Carrilho
    Journal of Gastroenterology, 2001, 36 : 476 - 485
  • [49] Long-term lamivudine treatment in anti-HBe positive chronic hepatitis B: An interim analysis
    Santantonio, T
    Sinisi, E
    Mazzola, M
    Insalata, M
    Guastadisegni, A
    Pastore, G
    JOURNAL OF HEPATOLOGY, 2001, 34 : 132 - 133
  • [50] Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B
    Da Silva, LC
    Pinho, JRR
    Sitnik, R
    Da Fonseca, LEP
    Carrilho, FJ
    JOURNAL OF GASTROENTEROLOGY, 2001, 36 (07) : 476 - 485
12345